drugset / Trial / NCT06691984
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Timeline
- Start
- 2024-12-09
- Primary completion
- 2029-01-02
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | — | Oral |
| Comparator | Cabazitaxel | Other / unclassified | — | Intravenous |
| Comparator | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Xaluritamig | Unknown | — | Intravenous |